These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 9241003)

  • 1. Brofaromine for social phobia: a multicenter, placebo-controlled, double-blind study.
    Lott M; Greist JH; Jefferson JW; Kobak KA; Katzelnick DJ; Katz RJ; Schaettle SC
    J Clin Psychopharmacol; 1997 Aug; 17(4):255-60. PubMed ID: 9241003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Moclobemide in social phobia: a controlled dose-response trial.
    Noyes R; Moroz G; Davidson JR; Liebowitz MR; Davidson A; Siegel J; Bell J; Cain JW; Curlik SM; Kent TA; Lydiard RB; Mallinger AG; Pollack MH; Rapaport M; Rasmussen SA; Hedges D; Schweizer E; Uhlenhuth EH
    J Clin Psychopharmacol; 1997 Aug; 17(4):247-54. PubMed ID: 9241002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Social phobia: the clinical efficacy and tolerability of the monoamine oxidase -A and serotonin uptake inhibitor brofaromine. A double-blind placebo-controlled study.
    Fahlén T; Nilsson HL; Borg K; Humble M; Pauli U
    Acta Psychiatr Scand; 1995 Nov; 92(5):351-8. PubMed ID: 8619339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversible monoamine oxidase-A inhibitors in social phobia.
    Liebowitz MR; Schneier F; Gitow A; Feerick J
    Clin Neuropharmacol; 1993; 16 Suppl 2():S83-8. PubMed ID: 8313403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The International Multicenter Clinical Trial Group on Moclobemide in Social Phobia. Moclobemide in social phobia. A double-blind, placebo-controlled clinical study.
    Eur Arch Psychiatry Clin Neurosci; 1997; 247(2):71-80. PubMed ID: 9177952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Placebo-controlled trial of moclobemide in social phobia.
    Schneier FR; Goetz D; Campeas R; Fallon B; Marshall R; Liebowitz MR
    Br J Psychiatry; 1998 Jan; 172():70-7. PubMed ID: 9534836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor.
    van Vliet IM; den Boer JA; Westenberg HG
    Eur Neuropsychopharmacol; 1992 Mar; 2(1):21-9. PubMed ID: 1638170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Personality traits in social phobia, II: Changes during drug treatment.
    Fahlén T
    J Clin Psychiatry; 1995 Dec; 56(12):569-73. PubMed ID: 8530333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine.
    Versiani M; Nardi AE; Mundim FD; Alves AB; Liebowitz MR; Amrein R
    Br J Psychiatry; 1992 Sep; 161():353-60. PubMed ID: 1393304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Social phobia: long-term treatment outcome and prediction of response--a moclobemide study.
    Versiani M; Amrein R; Montgomery SA
    Int Clin Psychopharmacol; 1997 Sep; 12(5):239-54. PubMed ID: 9466158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversible and selective inhibitors of monoamine oxidase A in mental and other disorders.
    Priest RG; Gimbrett R; Roberts M; Steinert J
    Acta Psychiatr Scand Suppl; 1995; 386():40-3. PubMed ID: 7717094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Moclobemide in the treatment of social phobia.
    Nutt D; Montgomery SA
    Int Clin Psychopharmacol; 1996 Jun; 11 Suppl 3():77-82. PubMed ID: 8923114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brofaromine in depression: a Canadian multicenter placebo trial and a review of standard drug comparative studies.
    Chouinard G; Saxena BM; Nair NP; Kutcher SP; Bakish D; Bradwejn J; Kennedy SH; Sharma V; Remick RA; Kukha-Mohamad SA
    Clin Neuropharmacol; 1993; 16 Suppl 2():S51-4. PubMed ID: 8313397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Canadian multicentre placebo-controlled study of a fixed dose of brofaromine, a reversible selective MAO-A inhibitor, in the treatment of major depression.
    Chouinard G; Saxena BM; Nair NP; Kutcher SP; Bakish D; Bradwejn J; Kennedy SH; Sharma V; Remick RA; Kukha-Mohamad SA
    J Affect Disord; 1994 Oct; 32(2):105-14. PubMed ID: 7829762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of citalopram and moclobemide in patients with social phobia: some preliminary findings.
    Atmaca M; Kuloglu M; Tezcan E; Unal A
    Hum Psychopharmacol; 2002 Dec; 17(8):401-5. PubMed ID: 12457375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of 19 double-blind placebo-controlled studies in social anxiety disorder (social phobia).
    Versiani M
    World J Biol Psychiatry; 2000 Jan; 1(1):27-33. PubMed ID: 12607230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Moclobemide in social phobia: a pilot open study. GRP Group. Groupe de Recherche en Psychopharmacologie.
    Bisserbe JC; Lépine JP
    Clin Neuropharmacol; 1994; 17 Suppl 1():S88-94. PubMed ID: 7954487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A cross-study comparison of the effects of moclobemide and brofaromine on actual driving performance and estimated sleep.
    Ramaekers JG; van Veggel LM; O'Hanlon JF
    Clin Neuropharmacol; 1994; 17 Suppl 1():S9-18. PubMed ID: 7954488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is there a role for selective monoamine oxidase inhibitor therapy in bulimia nervosa? A placebo-controlled trial of brofaromine.
    Kennedy SH; Goldbloom DS; Ralevski E; Davis C; D'Souza JD; Lofchy J
    J Clin Psychopharmacol; 1993 Dec; 13(6):415-22. PubMed ID: 8120155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Double-blind comparison of moclobemide and tranylcypromine in depression.
    Heinze G; Rossel L; Gabelic I; Galeano-Munoz J; Stabl M; Allen SR
    Pharmacopsychiatry; 1993 Nov; 26(6):240-5. PubMed ID: 8127928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.